Your browser is no longer supported. Please, upgrade your browser.
GT Biopharma, Inc.
Index- P/E- EPS (ttm)-3.49 Insider Own0.90% Shs Outstand23.74M Perf Week8.43%
Market Cap235.03M Forward P/E- EPS next Y-0.95 Insider Trans0.00% Shs Float19.73M Perf Month53.25%
Income-14.80M PEG- EPS next Q-0.04 Inst Own1.50% Short Float2.86% Perf Quarter32.35%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.00 Perf Half Y161.73%
Book/sh-6.50 P/B- EPS next Y- ROA- Target Price- Perf Year315.97%
Cash/sh0.22 P/C44.34 EPS next 5Y- ROE- 52W Range2.04 - 13.09 Perf YTD37.35%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-22.39% Beta0.08
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low397.59% ATR0.98
Employees2 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)64.13 Volatility11.57% 12.34%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.55 Prev Close9.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume567.04K Price10.16
Recom2.00 SMA2016.37% SMA5046.26% SMA200102.31% Volume56,042 Change2.62%
Apr-13-21Initiated B. Riley Securities Buy $21
Mar-17-21Initiated ROTH Capital Buy $25
Apr-19-21 07:00AM  
Apr-12-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 07:00AM  
Mar-17-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 08:30AM  
Mar-04-21 08:30AM  
Mar-02-21 03:00AM  
Feb-18-21 08:00AM  
Feb-16-21 08:00AM  
Feb-11-21 08:00AM  
Jan-19-21 09:00AM  
Jan-12-21 10:00AM  
Jan-04-21 09:45AM  
Dec-28-20 09:35AM  
Dec-21-20 11:00AM  
Dec-17-20 09:15AM  
Dec-14-20 09:05AM  
Dec-08-20 07:30AM  
Nov-18-20 07:30AM  
Nov-12-20 07:30AM  
Oct-15-20 07:45AM  
Oct-13-20 07:45AM  
Sep-22-20 07:45AM  
Aug-20-20 08:00AM  
Aug-04-20 08:00AM  
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.